GLOBESTAR THERAPEUTICS CORPORATION GlobeStar Therapeutics Corporation Stock
Equities
GSTC
US37960P1049
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0006 USD | 0.00% |
|
+20.00% | -33.33% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 1.79M 2.44M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -1.36M | Net income 2023 | -1M -1.36M | EV / Sales 2022 | - |
| Net Debt 2022 | 152K 207K | Net Debt 2023 | 366K 498K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.56
x | P/E ratio 2023 |
-0.76
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.42% |
More Fundamentals
* Assessed data
| 1 week | +20.00% | ||
| Current month | -25.00% | ||
| 1 month | -33.33% | ||
| 3 months | -45.45% | ||
| 6 months | -64.71% | ||
| Current year | -33.33% |
1 week
0.00
0.00
1 month
0.000.00
Current year
0.000.00
1 year
0.000.01
3 years
0.000.08
5 years
0.000.09
10 years
0.000.52
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 0.0006 | 0.00% | 8,665,112 |
| 24-05-16 | 0.0006 | +9.09% | 4,245,672 |
| 24-05-15 | 0.00055 | +37.50% | 45,051,822 |
| 24-05-14 | 0.0004 | -9.09% | 17,767,181 |
| 24-05-13 | 0.00044 | -12.00% | 32,880 |
Delayed Quote OTC Markets, May 17, 2024 at 03:51 pm
More quotes
GlobeStar Therapeutics Corporation (GlobeStar Therapeutics) is a clinical-stage pharmaceutical company. The Company is focused on introducing a patented formulation of drugs for the treatment of Multiple Sclerosis and other neurodegenerative diseases. The Company owns the global license from the inventors, who are based in Italy. The Company has acquired a license for a patented method of treating neurodegenerative diseases such as Multiple Sclerosis by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration and treating neurodegeneration. GlobeStar Therapeutics is initiating discussions with the Food and Drug Administration (FDA) on clinical trial design in preparation for FDA submission and approval pathway.
| 1st Jan change | Capi. | |
|---|---|---|
| -33.33% | 698K | |
| +33.63% | 50.85B | |
| -0.09% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +11.18% | 26.11B | |
| -21.95% | 19.13B | |
| +8.61% | 13.05B | |
| +28.31% | 12.16B | |
| +24.73% | 12.08B |
- Stock Market
- Equities
- GSTC Stock
